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Abstract 
 
This thesis is divided into two distinct parts: mutation and treatment of 
cancer. Each abstract is described separately. 
Molecular, cellular, and clinical studies have combined to demonstrate a 
contribution from the DNA cytosine deaminase APOBEC3B (A3B) to the overall 
mutation load in breast, head/neck, lung, bladder, cervical, ovarian, and other 
cancer types. However, the complete landscape of mutations attributable to this 
enzyme has yet to be determined in a controlled human cell system. In Chapter 
2, we report a conditional and isogenic system for A3B induction, genomic DNA 
deamination, and mutagenesis. Targeted sequencing of portions of TP53 and 
MYC demonstrated greater mutation accumulation in the A3B-eGFP exposed 
pools. Clones were generated and microarray analyses were used to identify 
those with the greatest number of SNP alterations for whole genome sequencing. 
A3B-eGFP exposed clones showed global increases in C-to-T transition 
mutations, enrichments for cytosine mutations within A3B-preferred trinucleotide 
motifs, and more copy number aberrations. The 293-based system characterized 
here still yielded a genome-wide view of A3B-catalyzed mutagenesis in human 
cells and a system for additional studies on the compounded effects of 
simultaneous mutation mechanisms in cancer.  
Personalized medicine includes the identification of the biomarkers and/or 
expression profiles important in the treatment of cancer. Cancer cell lines offer a 
representative diversity of molecular processes involved in both malignant 
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phenotypes as well as therapeutic responses. Coupling cancer line expression 
with high-throughput drug screens allows for examination of perturbed pathways 
that influence drug sensitivities. Here we use The Sanger Institute’s Genomics of 
Drug Sensitivity in Cancer to develop a bioinformatic and pathway analysis 
approach that identifies activation of the BCR pathway as an important biomarker 
in response to the tyrosine kinase inhibitor, dasatinib, used in hematologic cancer 
therapies. This approach establishes a process by which data from cell line 
repositories can be used to identify biomarkers associated with drug response in 
the treatment of cancers. 
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Chapter 1 
Introduction 
This thesis is divided into two distinct parts: mutation and treatment of 
cancer. The background of each will be done separately. 
Part I: Background for Mutational Processes  
It has long been suspected that cancer arises as an imprecise passing on 
of hereditary material of somatic cells. Indeed, over 100 years ago, through 
astute observation of dividing sea urchin cells Theodor Boveri discovered that an 
exact chromosome complement was necessary for controlled growth. Boveri 
hypothesized in 1902 that an aberrant number of chromosomes in a single cell 
gave rise to uncontrolled growth similar to a tumor(1). Since the time Boveri and 
his wife, Marcella, made these observations, many more observed the specifics 
of mutations and their contribution to oncogenesis.  
Viruses proved to be not only an exogenous source of cancer, but also 
communicable (2). Mutations accrued in irradiated mice resulted in tumors (3). 
More sources of mutations were added to the list of growing scientific 
understanding. These sources could be divided into two groups: exogenous and 
endogenous.  
Mutations have been accepted as one cause of cancer. But there are also 
beneficial uses for mutations. Indeed, we would still be bubbles in the primordial 
ooze rather than multi-cellular, multi-function beings had evolution not used 
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mutation to retool gene products into the complexity we see in the diversity of life 
forms.  
Within humans, 3 important mutational processes occur: antibody 
formation and diversification, foreign DNA restriction, and T-cell receptor 
rearrangements. I will describe in detail the first two processes. 
Controlled Endogenous Mutagenesis 
 Antibody Diversification 
Mutations are necessary for diversification during antibody production. 
Antibody diversity and specificity is a result of recombination of the heavy and 
light (either kappa or lambda) chain components of the future antibody. 
Recombination activating gene (RAG) enzymes are responsible for controlled 
cutting of variable, diversity, and joining (V(D)J) regions of the heavy chain (HC) 
which are then rejoined in a newly re-configured genetic sequence by non-
homologous end joining (NHEJ) (4). This process allows construction of 
antibodies with an enormous diversity of gene rearrangements. RAG1/2-assisted 
recombination also occurs at either the kappa or lambda light chain (LC) variable 
and joining (VJ) gene regions (Fig 1A-C). The heavy and light chains are 
presented together via disulfide bonds upon the IgM stem embedded in the 
plasma membrane. The new, unique configuration is now tested for efficacy 
against potential immunological threats.  
Activation-Induced Cytosine Deaminase (AID) is an enzyme responsible 
for removing amine groups from single-stranded cytosines. The resulting uracil 
lesion is mismatched with the no-longer-complementary guanine on the opposite 
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strand. This lesion can be repaired back to an error-free cytosine through base-
excision repair. However, the lesion can also result in mutation (Fig 2).  
1. Replication over the uracil results in a C>T transition,  
2. translesion synthesis can bring about C>T transitions or C>A 
transversions,  
3. mutagenic mismatch repair can result in transitions or 
transversions, 
4. and abasic sites left un-repaired may result in double-stranded 
breaks(5). 
AID deamination is responsible for somatic hypermutation (SHM) that 
modifies antibodies and diversifies them to acquire a “best fit” antibody to attack 
foreign invaders with precision (Fig 1D)(6). Class-switch recombination (CSR) 
occurs when AID-induced double-stranded breaks recombine via non-
homologous end joining to result in isotype of the antibody produced (Fig 1E)(4). 
Antibody construction is an orchestrated process and the enzymes involved are 
well controlled and largely sequester their activity to the antigen binding sites 
(hypervariable regions) of IGH, IGL (7).  
Foreign DNA Restriction 
Cellular immunity is a defense system against foreign DNA. It has been 
formed as a set of 7 genes in tandem on chromosome 22, decendents from AID: 
the APOBEC3 genes (Fig 4) (8). Like their progenitor, these genes also code for 
active cytosine deaminases (9). The canonical function of the APOBEC3 proteins 
is foreign DNA restriction in the cytoplasm during viral infection (10).  
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These enzymes deaminate DNA in the cytoplasm from viral infection or 
even uptake of foreign DNA material protecting the cell from infection or 
disruptive integration into host DNA (8,11–13). 
The enzymes work on single-stranded DNA of retroviruses deaminating 
cytosines and rendering the code ineffective in infection. The cytoplasmic 
localization of the APOBEC3s reflect their function as that is where foreign DNA 
first presents (14).  
Nuclear APOBEC3 Activity 
There are several APOBEC3s found in the nucleus (Fig 4). One important 
function of nuclear localization APOBEC3s is the suppression of Alu and LINE 
elements—ancient retrotransposon “jumping genes” (12,15–17) and therefore 
their nuclear occupation may be justified. The restriction of retro-elements does 
not require enzymatic activity (10). But are nuclear APOBEC3s enzymatically 
active? Can they deaminate genomic cytosines? 
Of the APOBEC3s found in the nucleus, APOBEC3B (A3B) is the only A3 
member that is exclusively nuclear (14,18). A3B is, therefore, a good candidate 
to study for evidence of genomic DNA mutation. What is the impact of A3B’s 
enzymatic activity in the nucleus. A3B’s enzymatic activity is potent (11). Is it 
under tight control, or does it, indeed cause mutation of the very DNA from which 
it came? 
Enzymatic-induced Mutation in Cancer 
During controlled breakage of the IGH region, the DNA is vulnerable to 
NHEJ with another region, or another chromosome altogether. AID was 
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discovered to be responsible for the t(8;14) chromosomal translocation involving 
the newly severed IGH gene region, that was destined to recombine within the 
same gene region, is now recombined with the MYC oncogene. This 
translocation juxtaposing the MYC gene under the influence of IGH’s strong 
promoter is the hallmark of Burkitt lymphoma (19). Balb/c mice are prone to 
spontaneously developing c-Myc/IgH translocations and plasmacytomas (20). 
However, Balb/c AID-/- mice do not develop neoplasms (19). Multiple other 
translocations with evidence of AID-assisted mutagenesis involving the IGH gene 
region have since been reported(21). This was the first example of the controlled 
mutation machinery of antibody formation contributing to an oncogenic 
translocation(19).  
Substrate Context Preference 
Given the distribution of cytosines in the genome, random chance would 
predict a pattern of C>T transition with a fairly equal chance of being positioned 
3’ of any one of the 4 bases. However, exhaustive analysis of substrate context 
revealed A3B has a strong preference for deaminating cytosines flanked by a 5’ 
T and 3’ W base (5’TCW3’ context). This signature mirrors the context of point 
mutations seen in multiple cancer patient samples (22–24). 
As described in Figure 2 the resulting uracils can be properly excised and 
repaired. However, mutations can occur if the repair of the site is incomplete or 
erroneously repaired(5). 
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A3B as Mutagen 
The APOBEC3 member most likely to cause mutations in human genomic 
DNA is A3B. Firstly, A3B has import mechanisms to the nucleus allowing it 
access to genomic DNA (18). It is the only member that has exclusive nuclear 
localization.  
Further, breast cancers with a high level of A3B expression also had 
significantly higher numbers of mutations within A3B’s preferred substrate 
context (22). Since first discovering the correlation between high A3B expression 
and mutation load in breast cancer, more cancers have been examined for their 
A3B expression, mutation load, and sequence context specific to A3B—the 
cytosine substrate preceded by a thymine at the 5’ position and followed by a 
weak base—adenine or thymine—in the 3’ position (5,23). The sequence context 
of mutations have been examined by whole genome sequencing of tumors 
(24,25). These studies show a mutational signature that is indicative of the 
enzymatic activity of an APOBEC3 as shown in vitro (22). 
The mounting data implicated A3B as a causal agent in mutations 
(5,22,23,26,27). However, there are implications that another cytosine 
deaminase, APOBEC3A, could be responsible for the mutation signature seen in 
breast cancer (28). Further, tumors from individuals with a germline deletion of 
the coding region of A3B also carry an APOBEC3 signature, even in patients 
homozygous for the deletion (29,30). If A3B was deleted, what was responsible 
for the mutations seen in these tumors? 
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The field required an investigation into what a single APOBEC3 molecule, 
A3B, could do to human genomic DNA. We, therefore, developed a clean, 
isogenic system to monitor A3B’s mutagenic impact over time and the genomic 
landscape it shaped. 
Statement of Thesis 
Given the increased mutational load of breast cancers with higher A3B 
expression, we decided to examine the accumulation of mutations by A3B in a 
controlled, isogenic cell line system to prove the causal link between A3B and 
resulting increased mutation load and context specificity. In an A3B-GFP 
doxycline-inducible system with a GFP control derived from the same clone, 2 
biological replicates were grown side-by-side and induced weekly for 10 weeks. 
Our hypothesis was that A3B over-expressing lines would accumulate more 
mutation over the course of the experiment compared to the GFP controls and 
that these mutations would prefer the TCW sequence, characteristic of A3B’s in 
vitro enzymatic activity. 
 
Part II: Background for Gene Expression  
Drug Prediction Profiles 
Components of Precision Medicine  
There are multiple components to precision medicine. Genetic profiles 
contribute to precision medicine through identification of:  
1. diagnostic and prognostic mutations,  
2. diagnostic and prognostic expression,  
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3. targeted treatment, and  
4. treatment metabolism by congenital variants. 
Each of these components will be briefly examined for their historical 
contributions to the overall campaign to successfully treat cancer (Fig 5). 
 Diagnostic Mutations 
The first structural chromosomal defect of cancer was identified with the 
discovery of the Philadelphia chromosome in 1959. Cytogenetic analysis of 
chronic myelogenous leukemia (CML) patients (in Philadelphia and so, thusly 
named) revealed a small chromosome that was soon discovered to be the 
product of the causal translocation between chromosomes 9 and 22 (31). The 
resulting derivative 22 contained a fusion gene of BCR (Breakpoint Cluster 
Region) and ABL. The BCR gene region should not be confused with B-cell 
Receptor, which shares its abbreviation. For this reason, the gene region will 
always be followed by the words “gene region.” 
ABL is a tyrosine kinase that is constitutively active when fused in the 
BCR gene region. This extremely specific translocation led to one of the first 
targeted therapies, albeit over 40 years after the initial discovery of the 
translocation.  
Imatinib mesylate was approved for use in the United States in 2001 and 
dramatically improved CML treatment and outcomes (32). Mainstream media 
responded with sensational headlines like Time’s, “There Is New Ammunition In 
the War Against Cancer. These Are the Bullets” with a picture of imatinib 
mesylate pills on the cover of the May 2001 edition (33). 
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 Imatinib mesylate is a targeted tyrosine kinase inhibitor and, at least 
initially, the hype seemed warranted. However, CML patients started relapsing. 
Their cancers had mutated or amplified the fusion gene so that imatinib mesylate 
no longer managed their disease (34). This highlights one of the difficulties in 
precision medicine: the moving target of treating a dynamic disease—one that 
can change, or is heterogeneous at the start of treatment. 
Prognostic Mutations 
The Döhner classification of chronic lymphocytic leukemia (CLL) is based 
on cytogenetic analysis identifying deletions, duplications, translocations, and 
aneusomies. The analysis stratifies patients into 5 prognostic groupings allowing 
practitioners and patients to make treatment decisions based on their prognostic 
classification (35).  
 Prognostic Expression 
Her2 expression is an example of a prognostic marker turned targeted 
therapy. The Her2 (ERBB2) protein is overexpressed in about 25% of breast 
cancers often due to gene amplification. Her2 amplified breast cancers were 
aggressive and patients were given a poor prognosis (36). Cleverly, a 
monoclonal antibody against Her2 was used to neutralize the proliferation signal 
from the amplified protein. A humanized form of the original mouse monoclonal 
was created to allow for patients’ immune system to better tolerate the presence 
of the foreign antibody (37). For Her2-amplified breast cancer, trastuzumab, 
turned a poor prognosis into a treatable disease (36,38–40).  
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Targeted Treatment 
Both imatinib mesylate and trastuzumab represent treatments targeted to 
mutations and expression respectively. Success of these molecular targeting 
therapies resulted in a race of clinicians and researchers looking for similar 
molecular aberrations in other cancer types. As a result, imatinib mesylate is now 
used as an effective treatment in gastrointestinal stromal tumors (41,42). 
Trastuzumab is used in treating Her2-amplified metastatic gastric cancer and 
gastroesophogeal junction adenocarcinoma (43–45). Thus, therapies designed 
for a specific cancer were found to have possible broader applications. A shift 
began in which cancer treatments were based on common genetic events, even 
across cancers of different tissue types. 
Drug Metabolism 
The final component of precision medicine to be discussed here is 
congenital variants of metabolism. Liver enzymes that either pre-process drugs 
from pro-drug inactive to active forms or break down drugs to be cleared have a 
variety of reported single nucleotide polymorphisms (SNPs). For example, 
Tamoxifen is an anti-estrogen drug but is only effective when converted by the 
liver enzyme CYP2D6 into its active endoxifen form (46). Single Nucleotide 
Polymorphisms (SNP) variants of CYP2D6 with less enzymatic activity convert 
less drug to endoxifen resulting in a weakened therapeutic benefit. However, 
even with enzymatically potent CYP2D6 variants, tamoxifen benefit can be 
reduced as other prescription drugs can reduce the activity of CYP2D6 (47). 
 
	 11	
Genetic Approaches to Predictive Problems 
Cytogenetic analysis was our first experience with diagnostic precision 
medicine—the discovery of the Philadelphia chromosome. Indeed, DNA analysis 
for mutations and variations make up a greater portion of clinically available tests 
for diagnosis, prognosis, targeted treatment, and metabolic variants.  
However, there has been a place for gene expression, even relatively 
early on with assays for receptors that classify tumors or indicate overexpression 
via immunohistochemistry (IHC). The technique was developed in 1941, long 
before the cancer field had a use for it (48). IHC and other immunofluorescent 
techniques in research labs have now become routine. In 1996, a Phase II trial to 
test patients for Her2 overexpression status via IHC, brought the utility into 
clinical precision medicine (49). 
The central dogma of biology: DNA makes RNA makes protein, would 
make the argument that what can be learned from the DNA is also in the RNA. 
And, importantly, it is the amount of RNA that may define cellular activity, 
including response to therapies. In Chapter 3, I make use of expression data 
from cell lines to describe expression signatures predictive of drug response.  
Precision Medicine Summary 
The patient-specific cancer characteristics described above also 
determine which therapies will or won’t be effective. Further, a patient’s 
congenital enzymatic make-up determines if drugs are converted into active 
conformations, metabolized and cleared too quickly to illicit a response, or too 
slowly and build up to toxic levels. The multiple layers of information that can be 
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gathered from a patient and tumor make precision medicine difficult and highlight 
a necessity to integrate genetic data from a larger body of evidence.  
Commonalities Across Cancers 
Tumor suppressors and proto-oncogenes are within every non-tumor cell. 
The disruption of their function can be found across different cancer types. For 
example, the ALK gene was first found rearranged in large-cell lymphoma has 
been found in non-small cell lung carcinoma and clear cell renal cell carcinoma 
(50–52). TP53 is estimated to be mutated, deleted, or silenced in nearly every 
type of cancer with frequencies ranging from 10% of hematologic malignancies to 
nearly 100% of high-grade serous ovarian cancer (53). Likewise, mis-regulation 
of MYC-targeted genes is involved in a statistically significant proportion of 11 of 
the 17 cancer types examined in the the Cancer Genome Atlas (TCGA) (54). 
Discoveries of similar aberrations across cancer types has led to a movement of 
classification of cancer into genetic-based categories rather than the more broad 
categories based on histology or tissue of origin (55–57). 
The difficulties presented by variant components of precision medicine 
require utilizing information from all cancers. Large databases representing 
multiple cancer types allow us to cross tissue barriers as repositories are 
collections of multiple cancer types, tissues, stages, and individuals. Chapter 3 
utilizes big data from multiple cancer types.  
Opportunities in Public Repositories 
Big data presents the opportunity to explore the gene expression-drug 
response relationship in greater detail and across multiple cancer types. Cancer 
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cell line collections such as the NCI-60, Genomics of Drug Sensitivity in Cancer 
(GDSC), and Cancer Cell Line Encyclopedia (CCLE) offer mutation status, 
expression profiles, and drug response data (58–60). 
The GDSC has 1074 cell lines with whole-genome sequence, micro-array 
expression data, and response profiles to 265 drugs (58). Examination of the 
expression profiles of cell lines derived from diverse primary tumors and their 
corresponding response to drugs allows us to dissect important gene and 
pathway expression that contributes to either response or resistance to a drug. 
Once these patterns are established and tested clinically, patient tumor profiles 
could direct therapy selection toward a more effective treatment. 
Diving In to Big Data 
The gene-drug approach described above can, as I show in Chapter 3, be 
extended beyond one gene to include multiple genes of a pathway. In order to 
accomplish this, multiple steps in limiting and classifying the data were 
employed.  
Firstly, we subset the cell lines to only include B-cell malignancies, leaving 
us with expression data for 94 lines. This was done to limit any confounding 
impact of tissue-specific expression on analysis, but still benefit from the 
combination of multiple cancer types to increase sample size as well as broaden 
what is understood about the all the cancers of B-cell origin. This is a small 
version of the pan-cancer analysis described earlier.  
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Secondly, we examined 14 drugs with targets currently being used for 
treatment in B-cell malignancies. We chose to focus on Dasatinib, which is a 
multi-kinase inhibitor.  
Area under the survival curve (AUSC) is a measurement of drug response 
that is, in this data set, normalized between 0 and 1. Lines with an AUSC for a 
drug that approaches 1 is more resistant than a line that has a value of 0.5 or 
less. It’s important to note that there is no specific criterion for what is responsive 
in these studies. Relative responsiveness is the measure by which value cutoffs 
for AUSC were based. Cutoffs were chosen based on breaks in the AUSC values 
that we assess represented a natural cutoff between a physiological response to 
the drug. These separations in AUSC values are drug-specific and, in some 
drugs, do not exist, but rather a gradual, continuous, distribution of AUSC values 
is observed. 
We describe lines as Responders of dasatinib when they have an AUSC 
of less than 0.75 with the additional criterion of 50% of cell death (IC50) at a drug 
concentration below the maximum testing concentration divided by 4. The IC50 
criterion was to ensure that there was cell death assayed well within the survival 
curve plot. There were 14 Responders of the 71 lines for which drug testing was 
available. We described lines as Non-Responders when their AUSC was greater 
than 0.98. This is an extremely high value and there is no ambiguity that these 
lines’ metabolism was unaffected by dasatinib. 
It was important that we have cell lines that displayed extreme responses 
so as not to confound analysis. We identified differential expression between 
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Non-Responders and Responders. Once a we narrowed down candidate gene 
expression markers of dasatinib response, we examined the expression of these 
candidates in the remaining 46 llines. We were looking for trends in lines with 
partial response or resistance. Did they have expression values similar to their 
nearest extreme responders? 
B-cell Development 
 The hematopoietic stem cell starts down a course of differentiation that 
has multiple bifurcations and destinations. The one arm we will focus on here is 
that of B-cell differentiation. The differentiation of a B-cell is marked by surface 
receptors, activation of the B-cell receptor (BCR) pathway, and the maturation of 
the antibody described in Part I of this introduction (Fig 6).  
The pluripotent pre-B cell has an activated B-cell receptor pathway with 
high expression of BCR components such as CD19, CD79A, and CD79B 
presented on the surface of the cell (61). The HC first recombines the D-J 
regions followed by joining this newly recombined section with a rearrangement 
of the V region. The pre-B-cell adds the HC to the BCR assembly as prototype of 
an antibody with a surrogate LC substituting for the yet-to-be recombined IGL 
region (either kappa or lambda). Should the surrogate LC bind sufficiently bind 
and present the HC, the new pro-B cell moves forward in differentiation and 
replaces the surrogate LC with the newly-formed LC to the BCR ensemble and 
the naïve cell lies in wait. Once stimulated by an antigen, the intercellular 
portions of CD79A and CD79B are phosphorylated and a proliferation and 
survival cascade ensues in the mature B cell (61).  
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After the BCR has signaled, its usefulness is obsolete and the cell 
downregulates the BCR pathway components. The fully mature product of the 
differentiated B-cell, the plasma cell, in fact, has essentially no expression or 
presentation of BCR components, such as CD19 (61).  
The subset of B-cell malignancies from the GDSC has expression data for 
71 cell lines, which also have drug response for dasatinib. It is to be expected 
that molecules involved in differentiation will be differentially expressed based on 
at what stage in development the malignancy arose. What is also expected is the 
cell lines carry enough in common to reveal what is truly different between the 
Responders and Non-Responders. 
 
Statement of Thesis 
We hypothesize that the phenotype of extreme response and non-
response to drug treatment in cell lines must be due to differences between the 
lines that can be revealed by analysis of RNA expression. We focused our 
attention on dasatinib response in B-cell malignancies. We augmented our 
analysis by including pathway analsyis of the differentially expressed genes. Our 
gene expression response signature was confirmed by validating the biomarkers 
on untested cell lines and primary patient samples and supported by outcomes of 
a clinical trial. 
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Fig	1.	Antibody	Formation:	Use	for	Controlled	Mutagenesis	
A) The HC Variable, Diversity, and Joining (V(D)J) loci undergo recombination 
via the double-stranded breaks induced by the RAG enzymes (depicted as white 
circles). Non-homologous end joining joins breaks to reconfigure the locus into a 
unique region.  
B) The LC (either the kappa or lambda locus) also undergoes recombination, 
however there is no diversity sequence within the LC. 
C) After being transcribed and translated, the antibody assembles. The HC ends 
in a constant region (black) that abuts to the IgM locus that creates the “stem” of 
the antibody. The LC also ends in a constant region. 
D) Somatic Hypermutation (SHM) occurs as AID deaminates cytosines within the 
heavy and light chain loci. SHM of the HC is depicted here with the mutations 
arrowed on resultant antibody.  
E) Class Switch Recombination (CSR) occurs when the AID-induced lesion 
results in a double-stranded break that recombines the locus designating the 
type of antibody to be produced.  
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Fig.	2	Outcomes	of	A3B	Deamination	
	
A deaminated cytosine has multiple outcomes. Repair enzymes can, excise, and 
replace the cytosine resulting in error-free repair. However, all along the process 
of repair, mutations can result as  
1) the lesion is used as a template during replication  
2) error-prone mismatch repair can result in transition or transversions  
3) Translesion synthesis with an error-prone polymerase can also result in 
transition and transversions.  
4) Double-stranded breaks can occur at weakened abasic sites or when two 
abasic sites are near and nicked with AP endonuclease. 
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Fig 3. APOBEC3 Family of Cytosine Deaminases 
A schematic representing the location of the 7 APOBEC3 family members in 
tandem on chromosome 22. The cell representations on the right show the sub-
cellular localization of each family member corresponding to the color scheme. 
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Fig.	4	Precision	Medicine	in	Cancer	Timeline	
Examples of Diagnostic, Prognostic, Treatment, and Metabolic components of 
cancer care throughout recent history. 
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Fig	5.	B-cell	Differentiation 
The schematic represents B-cell differentiation and antibody maturation from left 
to right. The lymphoid stem cell commits to the b-cell lineage and undergoes D-J 
rearrangement of the IGH region as a Pro-B cell. Later in this stage the variable 
region recombines with the newly formed DJ region. Entering the Pre-B cell 
stage, the HC is displayed along with a surrogate LC. If successful binding of the 
surrogate LC with the HC occurs, the LC is recombined and added to the CD79A 
and CD79B components with the IgM stem at the surface of the immature B cell. 
The naïve B cell travels to secondary lymph tissues to wait for antigen 
stimulation. Upon antigen stimulation, the intercellular BCR intercellular 
components are phosphorylated and a signaling cascade results in proliferative 
and survival signals. Class switch recombination in the mature B cell results in 
the formation of antibody isotypes. Receptors and molecules of the BCR pathway 
are shown below as bars that extend across the differentiation stages where they 
are most expressed. 
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Overview 
Molecular, cellular, and clinical studies have combined to demonstrate a 
contribution from the DNA cytosine deaminase APOBEC3B (A3B) to the overall 
mutation load in breast, head/neck, lung, bladder, cervical, ovarian, and other 
cancer types. However, the complete landscape of mutations attributable to this 
enzyme has yet to be determined in a controlled human cell system. We report a 
conditional and isogenic system for A3B induction, genomic DNA deamination, 
and mutagenesis. Human 293-derived cells were engineered to express 
doxycycline-inducible A3B-eGFP or eGFP constructs. Cells were subjected to 10 
rounds of A3B-eGFP exposure that each caused 80-90% cell death. Control 
pools were subjected to parallel rounds of non-toxic eGFP exposure, and 
dilutions were done each round to mimic A3B-eGFP induced population 
fluctuations. Targeted sequencing of portions of TP53 and MYC demonstrated 
greater mutation accumulation in the A3B-eGFP exposed pools. Clones were 
generated and microarray analyses were used to identify those with the greatest 
number of SNP alterations for whole genome sequencing. A3B-eGFP exposed 
clones showed global increases in C-to-T transition mutations, enrichments for 
cytosine mutations within A3B-preferred trinucleotide motifs, and more copy 
number aberrations. Surprisingly, both control and A3B-eGFP clones also elicited 
strong mutator phenotypes characteristic of defective mismatch repair. Despite 
this additional mutational process, the 293-based system characterized here still 
yielded a genome-wide view of A3B-catalyzed mutagenesis in human cells and a 
system for additional studies on the compounded effects of simultaneous 
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mutation mechanisms in cancer.  
Introduction 
Cancer genome sequencing studies have defined approximately 30 distinct 
mutation signatures (reviewed by (27,62–64)). Some signatures are large-scale 
confirmations of established sources of DNA damage that have escaped repair. 
The largest is water-mediated deamination of methyl-cytosine bases, which 
manifest as C-to-T transitions in genomic 5’-CG motifs (65). This process 
impacts almost all cancer types and accumulates as a function of age. Other well 
known examples include ultraviolet radiation, UV-A and UV-B, which crosslink 
adjacent pyrimidine bases and result in signature C-to-T transitions (66), and 
tobacco mutagens such as nitrosamine ketone (NNK), which metabolize into 
reactive forms that covalently bind guanine bases and result in signature G-to-T 
transversions (67). These latter mutagenic processes are well known drivers of 
skin cancer and lung cancer, respectively, but also contribute to other tumor 
types. A lesser-known but still significant example of a mutagen is the dietary 
supplement aristolochic acid, which is derived from wild ginger and related plants 
and metabolized into reactive species that covalently bind adenine bases and 
cause A-to-T transversions(68,69). Aristolochic acid mutation signatures are 
evident in urothelial cell, hepatocellular, and bladder carcinomas. Other 
confirmed mutation sources include genetic defects in recombination repair 
(BRCA1, BRCA2, etc.), post-replication mismatch repair (MSH2, MLH1, etc.), 
and DNA replication proofreading function, which manifest as microhomology-
mediated insertion/deletion mutations, repeat/microsatellite slippage mutations, 
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and transversion mutation signatures, respectively(27,65,70).  
 The largest previously undefined mutation signature in cancer is C-to-T 
transitions and C-to-G transversions within 5’-TC dinucleotide motifs(24,65,71). 
This mutation signature occurs throughout the genome, as well as less frequently 
in dense clusters called kataegis. This signature is ascribable to the enzymatic 
activity of members of the APOBEC family of DNA cytosine to uracil 
deaminases(22–24,65,71,72). Human cells encode up to 9 distinct APOBEC 
family members with demonstrated C-to-U editing activity, and 7/9 have been 
shown to prefer 5’-TC dinucleotide motifs in single-stranded DNA substrates: 
APOBEC1, APOBEC3A, APOBEC3B (A3B), APOBEC3C, APOBEC3D, 
APOBEC3F, and APOBEC3H. In contrast, AID and APOBEC3G prefer 5’RC and 
5’CC, respectively (R = purine; reviewed by(73,74)). The size and similarity of 
this protein family, as well as the formal possibility that another DNA damage 
source may be responsible for the same mutation signature(75), have made DNA 
sequencing data and informatics analyses open to multiple interpretations. 
 However, independent (14,22) and subsequent (5,23,28,72,76–80) 
studies indicate that at least one DNA deaminase family member, A3B, has a 
significant role in causing these types of mutations in cancer. First, A3B localizes 
to the nucleus throughout the cell cycle except during mitosis when it appears 
excluded from chromatin(14). Second, A3B is upregulated in breast cancer cell 
lines and primary tumors at the mRNA, protein, and activity levels(5,22,81). 
Third, endogenous A3B is the only detectable deaminase activity in nuclear 
extracts of many cancer cell lines representing a broad spectrum of cancer types 
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(breast, head/neck, lung, ovarian, cervix, and bladder (5,22,81)). Fourth, 
endogenous A3B is required for elevated levels of steady state uracil and 
mutation frequencies in breast cancer cell lines(22). Fifth, overexpressed A3B 
induces a potent DNA damage response characterized by g-H2AX and 53BP1 
accumulation, multinuclear cell formation, and cell cycle deregulation(22,28,76). 
Sixth, A3B levels correlate with overall mutation loads in breast and head/neck 
tumors (22,77). Seventh, the biochemical deamination preference of recombinant 
A3B, 5’TCR, is similar to the actual cytosine mutation pattern observed in breast, 
head/neck, lung, cervical, and bladder cancers(5,22,23). Eighth, human 
papillomavirus (HPV) infection induces A3B expression in several human cell 
types, providing a link between viral infection and the observed strong APOBEC 
mutation signatures in cervical and some head/neck and bladder cancers(82–
84). Ninth, the spectrum of oncogenic mutations in PIK3CA is biased toward 
signature A3B mutation targets in HPV-positive head/neck cancers(77). Finally, 
high A3B levels correlate with poor outcomes for estrogen receptor-positive 
breast cancer patients (79,80,85). 
 Despite this extensive and rapidly growing volume of genomic, 
molecular, and clinical information on A3B in cancer, the full breadth of this 
enzyme’s activity on the human genome has yet to be determined. Here we 
report further development of a human 293 cell-based system for conditional 
expression of human A3B. The results reveal, for the first time in a human cell 
line, the genomic landscape of A3B mutagenesis.  
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Materials and Methods 
Cell Lines 
We previously reported T-REx-293 cells that conditionally express A3B (22). 
However, the mother, daughter, and granddaughter lines described here are new 
in order to ensure a single cell origin and have all of the controls derived in 
parallel. T-REx-293 cells were cultured in high glucose DMEM (Hyclone) 
supplemented with 10% FBS and 0.5% Pen/Strep. Single cell derived mother 
lines, A and C, were obtained by limiting dilution in normal growth medium. 
These mother clones were transfected with linearized pcDNA5/TO-A3Bintron-
eGFP (A3Bi-eGFP) or pcDNA5/TO-eGFP vectors (22,86), selected with 200 
µg/mL hygromycin, and screened as described in the main text to identify drug-
resistant daughter clones capable of Dox-mediated induction of A3Bi-eGFP or 
eGFP, respectively. The encoded A3B enzyme is identical to “isoform a” in 
GenBank (NP_004891.4). GFP flow cytometry was done using a FACSCanto II 
instrument (BD Biosciences). 
 
Immunoblots  
Whole cell lysates were prepared by suspending 1x106 cells in 300µL 10x 
reducing sample buffer (125mM Tris pH 6.8, 40% Glycerol, 4%SDS, 5% 2-
mercaptoethanol and 0.05% bromophenol blue). Soluble proteins were 
fractionated by 4% stacking and 12% resolving SDS PAGE, and transferred to 
PVDF membranes using a wet transfer BioRad apparatus. Membranes were 
blocked for 1 hr in 4% milk in PBS with 0.05% sodium azide. Primary antibody 
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incubations, anti-GFP (JL8-BD Clontech) and anti-b-actin (Cell Signaling) were 
done in at a 1:1000 dilution in 4% milk diluted in PBST, and incubation conditions 
ranged from 4-8 degrees C for 2-16 hrs. Membranes were then washed 3 times 
for 5 minutes in PBST. Secondary antibody incubations, anti-mouse 680 
(1:20000) and anti-rabbit 800 (1:20000), were done in 4% milk diluted in PBST 
with 0.01% SDS, and incubation conditions ranged from 4-8 degrees C for 2-16 
hrs. The resulting membranes were washed 3 times for 5 minutes in PBST and 
imaged using Licor instrumentation (Odyssey). 
 
DNA Deaminase Activity Assays  
This assay was adapted from published procedures (81,87). Whole-cell extracts 
were prepared from 1x106 cells by sonication in 200µL HED buffer (25mM 
HEPES, 5mM EDTA, 10% glycerol, 1mM DTT, and one tablet protease inhibitor-
Roche per 50mL HED buffer). Debris was removed by a 30 min maximum speed 
spin in a tabletop micro-centrifuge at 4 degrees C. The supernatant was then 
used in 20µL deamination reactions that contained the following: 1µL of 4pM 
fluorescently-labeled 43-mer oligo (5’-
ATTATTATTATTCGAATGGATTTATTTATTTATTTATTTATTT-fluorescein) 
containing a single interior 5’-TC substrate, 9.25µL UDG (NEB), 0.25µL RNase, 
2µL 10x UDG buffer (NEB), 16.5µL lysate. Reactions were incubated at 37 
degrees C for 1h. 2µL 1M NaOH was added and reaction was heated to 95 
degrees C in a thermocycler for 10 min. 22µL of 2x formamide loading buffer was 
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added to each sample. 5µL of each reaction was fractionated on a 15% TBE 
Urea Gel and imaged using a SynergyMx plate reader (BioTek).  
 
Differential DNA Denaturation (3D) PCR Experiments 
This assay was adapted from published procedures (22,88). Genomic DNA was 
extracted from samples using a PureGene protocol (Gentra) and quantified using 
Nanodrop instrumentation (ThermoFisher Scientific). 20 ng of genomic DNA was 
subjected to one round of normal high denaturation temperature PCR using Taq 
Polymerase (Denville) and primers for MYC (5’-ACGTTAGCTTCACCAACAGG 
and 3’TTCATCAAAAACATCATCATCCAG) or TP53 
(5’GAGCTGGAGCTTAGGCTCCAGAAAGGACAA and 
3’TTCCTAGCACTGCCCAACAACACCAGC). 383 bp and 376 bp PCR products 
were purified and quantified using qPCR with nested primer sets and SYBR 
Green detection (Roche 480 LightCycler; 
5’ACGAGGAGGAGAACTTCTACCAGCA and 
3’TTCATCTGCGACCCGGACGACGAGA for MYC and 
5’TTCTCTTTTCCTATCCTGAGTAGTGGTAA and 
3’TTATGCCTCAGATTCACTTTTATCACCTTT for TP53). Equivalent amounts of 
each PCR product were then used for 3D-PCR using the same nested PCR 
primer sets. The resulting 291 and 235 bp products were fractionated by agarose 
gel electrophoresis, purified using QIAEX II (Qiagen), cloned into a pJet vector 
(Fermentas), and subjected to sequencing (GENEWIZ). Alignments and mutation 
calls were done with Sequencher (Gene Codes Corporation).  
	 35	
 
SNP Analysis.  
Granddaughter clones were established by limiting dilution after the final pulse 
round. Genomic DNA was prepared using the Gentra PureGene kit (Qiagen, 
Valencia, CA, quantified by agarose gel staining with ethidium bromide and by 
NanoDrop measurements (Thermo Scientific, Wilmington, DE), and subjected to 
SNP analyses by Source BioScience (Cambridge, UK) using the Human 
OmniExpress-24v1-0 BeadChip (Illumina, San Diego, CA). Raw data were pre-
processed in GenomeStudio using the Genotyping Module (Illumina, San Siego, 
CA). Genotype clustering was performed using the humanomniexpress_24v1-
0_a cluster file, whereby probes with a GenCall score below 0.15, indicating low 
genotyping reliability, were discarded. All samples passed quality control as 
assessed by call rates and frequencies. Genotypes for a total of 716,503 probes 
were used for further analyses. 
By comparing the genotypes of the granddaughter clones with their 
respective mother clones, six classes of base substitutions could be determined 
(C-to-T, C-to-G, C-to-A, T-to-G, T-to-C, and T-to-A). For example, a C-to-T 
transition occurred if the C/C genotype of the mother clone changed to a C/T 
genotype in the granddaughter clone. Given the design of some microarray 
probes (i.e., some probes detect the Watson-strand rather than the Crick-strand), 
a change from a G/G in the mother clone to a G/A genotype in the granddaughter 
clone was also scored as a C-to-T transition. 
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Chromosomal abnormalities in the genomes of granddaughter clones were 
identified with Nexus Copy Number 7.5 software (BioDiscovery, Hawthorne, CA), 
using the matched mother clone as a reference. SNPRank segmentation was 
applied and the segmented copy number data were further processed with the 
Tumor Aberrations Prediction Suite (TAPS) to obtain allele-specific copy number 
profiles (89). All analyses were performed using the R statistical environment 
(http://www.R-project.org). The number of copy number alterations in the A3B-
eGFP pulsed clones were determined based on the difference between the 
segment copy number counts of the A3B-eGFP pulsed clones and the eGFP 
pulsed clones. Segments which the eGFP pulsed granddaughter clones were not 
identical or had CN of 0 were excluded. These were subsequently binned by 
copy number loss or gain. All SNP data sets have been deposited in the NCBI 
GEO database under accession code GSE78710. 
 
Whole Genome Sequencing (WGS) 
Library preparation and sequencing was performed by the Beijing Genome 
Institute (BGI) on the Illumina X Ten platform to an average of 34.5 ± 2.8 fold 
coverage using purified DNA from Pulse 10 subclone extractions described in the 
SNP methods. Sequences were aligned to the hg19 reference genome using 
BWA. PCR duplicates were marked and removed with Picard-tools (Broad). 
Somatic mutation calling was conducted using mpileup (SamTools), VarScan2 
(WashU), and MuTect (Broad). Mutations detected by both VarScan2 and 
MuTect were kept as true somatic mutations. VarScan2 was run using 
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procedures describe by de Bruin and coworkers(78). MuTect was run using 
default parameters. Alignments from CG1 and CG2 were used as “normal” 
controls for CA1 and CA3. Alignment from AG3 was used as the as “normal” 
control for AA3. CG1 and CG2 were used as normals for each other in order to 
determine their somatic mutations. Somatic mutations that were called against 
multiple “normal” genomes were merged to increase detection rates by 
overcoming regions of poor sequence coverage unique to either “normal” 
genome. Variants occurring at an allele frequency greater than 0.5 or falling into 
repetitive regions or those with consistent mapping errors were removed as 
described (78). Somatic indels were called by VarScan2 and filtered using the 
same methods described above. Separation of mutation signatures present in 
our WGS data was performed by the Somatic Signatures R package using 
nsNMF decomposition instead of Brunet NMF decomposition as described by 
Covington and colleagues (90). Mutation strand asymmetries were analyzed 
using somatic mutations from all samples and the AsymTools MatLab software 
(90). All raw sequences are available from NCBI SRA under project number, 
PRJNA312357. 
 
Results 
System for conditional A3B expression 
Previous studies have demonstrated that A3B over-expression induces a strong 
DNA damage response resulting in cell cycle aberrations and eventual cell death 
(14,22,28,76,86). To be able to control the degree of A3B-induced genotoxicity, 
	 38	
we built upon our prior studies (22) by establishing a single cell-derived isogenic 
system for conditional and titratable expression of this enzyme. T-REx-293 cells 
were subcloned to establish an isogenic “mother” line, which was then 
transfected stably with a doxycycline (Dox) inducible A3B-eGFP construct or with 
an eGFP vector as a negative control. The resulting “daughter” clones were 
screened by flow cytometry to identify those that were non-fluorescent without 
Dox (i.e., non-leaky) and uniformly fluorescent with Dox treatment (Fig 1A). 
Daughter clones were also screened for Dox-inducible overexpression of A3B-
eGFP or eGFP by anti-GFP immunoblotting (Fig 1B). A3B-eGFP clones were 
uniformly GFP-negative without Dox treatment, but eGFP only clones showed a 
low level of leaky expression possibly related to greater protein stability. As 
additional confirmation, the functionality of the induced A3B-eGFP protein was 
tested using an in vitro ssDNA deamination assay using whole cell extracts (87). 
As expected, only extracts from Dox-treated A3B-eGFP cells elicited strong 
ssDNA C-to-U editing activity as evidenced by the accumulation of the 
deaminated and hydrolytically cleaved reaction products (labeled P in Fig 1C; 
see Methods for details). Nearly identical results were obtained with a parallel 
set of independently derived daughter clones (Fig 1D-E). 
 
Iterative rounds of A3B exposure 
To establish reproducible A3B induction conditions, a series of cytotoxicity 
experiments was done using a range of Dox concentrations. 10,000 T-REx-293 
A3B-eGFP cells were plated in 10 cm plates in triplicate, treated with 0, 1, 4, or 
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16 ng/mL Dox, incubated 14 days to allow time for colony formation, and 
quantified by crystal violet staining. As expected, higher Dox concentrations led 
to greater levels of toxicity (Fig 2A, B). Interpolation from a best-fit logarithmic 
curve indicated that 2 ng/mL Dox (C-series daughter clone) or 1 ng/mL Dox (A-
series daughter clone) would cause 80-90% cytotoxicity, and this concentration 
was selected for subsequent experiments. Taken together with the measured 
doubling times of daughter clones, each A3B-eGFP induction series was 
estimated to span 7 days (represented in the workflow schematic in Fig 2C).  
Each T-REx-293 A3B-eGFP daughter clone was then subjected to 10 
rounds of A3B-eGFP induction and recovery (Fig 2C). Iterative exposures to 
A3B-eGFP were expected to generate randomly dispersed mutations throughout 
the genome. Ten rounds of A3B-eGFP induction were chosen as a sufficient 
regimen for the cells to accumulate readily detectable levels of somatic mutation 
as a proof-of-concept for this inducible system. Moreover, this approach left open 
the option to go back and characterize an intermediate round, or pursue 
additional rounds should analyses require less or more mutations, respectively. 
 A potential pitfall of this experimental approach is the possibility of 
selecting cells that have inactivated the A3B expression construct or the capacity 
for induction to avoid the cytotoxic effects of overexpressing this DNA 
deaminase. Aliquots of cells from each pulse series were therefore periodically 
tested by flow cytometry for A3B-eGFP inducibility, western blot for protein 
expression, and ssDNA deamination assays for enzymatic activity (e.g., Fig 1). 
Even after the tenth induction series, the A3B-eGFP daughter clones performed 
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similar to original daughter cultures as well as to daughter cultures that had been 
grown continuously in parallel to the Dox-exposed experimental cultures and 
diluted to mimic the population dynamics caused by each A3B-eGFP exposure 
(e.g., Fig 1). These observations indicate that, despite negative selection 
pressure imposed by A3B-eGFP mediated DNA damage, resistance or escape 
mechanisms did not become overt. 
 
Targeted DNA sequencing provides evidence for A3B mutagenesis 
Next, target gene 3D-PCR and sequencing were used to determine if the cells 
within each daughter culture had accumulated detectable levels of mutation after 
10 rounds of A3B-eGFP exposure. 3D-PCR is a technique that enables the 
preferential recovery of DNA templates with C-to-T transitions and/or C-to-A 
transversions, because these mutations cause reduced hydrogen bonding 
potential and yield DNA molecules that can be amplified at PCR denaturation 
temperatures lower than those required to amplify the original non-mutated 
sequences (11,22,91). MYC and TP53 were selected as target genes for this 
analysis because prior work by our lab with transiently over-expressed A3B and 
by others with related A3 family members has demonstrated that these genomic 
regions are susceptible to enzyme-catalyzed deamination (19,22,88,92–97). 
The 3D-PCR and DNA sequencing analyses revealed substantially more 
mutations in MYC and TP53 in A3B-eGFP exposed cells in comparison to 
controls (Fig 2D-G). For instance, in the C-series daughter clone 43 mutations, 
mostly C-to-T transitions, were evident in MYC amplicons from A3B-eGFP 
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exposed cultures, whereas only 8 mutations were found in a similar number of 
control amplicons (mutation plot on left side of Fig 2D; p=0.00036, Student's two-
tailed t-test). The mutation load per amplicon was also higher (pie graph on right 
side of Fig 2D). Similar results were obtained for TP53 (Fig 2E; p=0.11, 
Student's two-tailed t-test), as well as for both MYC and TP53 in a parallel set of 
independently derived A-series daughter clones (Fig 2F, 2G; p<0.0001 and 
p<0.0001, respectively, Student's two-tailed t-test). Taken together, these results 
provided strong confirmations that 10 rounds of A3B-eGFP exposure caused 
increased levels of genomic DNA mutagenesis. 
 
Genome wide mutation analyses 
The experiments described used pools of cells and, due to the largely stochastic 
nature of the A3B mutational process and the duration of the pulse series, each 
pool would be expected to manifest extreme genetic heterogeneity. This 
complexity would constrain a standard deep sequencing approach by enabling 
only the earliest arising mutations to be detected in the pool because most 
subsequent mutations would persist at frequencies too low for reliable detection. 
To reduce this complexity to a manageable level and be able to investigate the 
mutational history of a single cell exposed to iterative rounds of either A3B-eGFP 
or eGFP, we used limiting dilution to generate “granddaughter” subclones from 
the tenth generation daughter pools. The strength of this strategy is that any new 
base substitution in a single daughter cell, which occurred between the time the 
daughter clone was originally generated until the recovery period following the 
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tenth Dox treatment, would be fixed in the granddaughter clonal population at a 
predictable allele frequency depending on local chromosome ploidy (i.e., new 
mutations would be expected at 50% in diploid regions, 33% in triploid regions, 
25% in tetraploid regions, etc., of the 293 cell genome).  
The dynastic relationship between mother, daughter, and granddaughter 
clones is shown in Fig 3A. To provide initial estimates of the overall level of new 
base substitution mutations, genomic DNA was extracted from each 
granddaughter clone and subjected to single nucleotide polymorphism (SNP) 
analysis using the Illumina OmniExpress Bead Chip. A base substitution 
mutation was defined as a clear SNP difference between each daughter clone 
and her respective granddaughter. These analyses revealed a wide range of 
SNP alterations among granddaughter clones, ranging from a low of <500 in the 
C-series eGFP expressing granddaughter subclone CG1 to a high of over 8,000 
in the A-series A3B-eGFP expressing granddaughter subclone AA3 (Fig 3B). 
This extensive variability was expected based on the sublethal Dox concentration 
used in each exposure round, the randomness of granddaughter clone selection, 
and the stochastic nature of the mutation processes. Nevertheless, A3B-eGFP 
exposed granddaughter clones had an average of 3.4-fold more new cytosine 
mutations than the eGFP controls (averages shown by dashed vertical lines in 
Fig 3B). Sanger sequencing of cloned PCR products was used to confirm 
several distinct SNP alterations and provide an orthologous validation of this 
array-based approach (e.g., representative chromatograms of mutations in 
granddaughter CA1 versus CG2 in Fig 3C). In addition, hundreds more genomic 
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copy number alterations were evident in A3B-eGFP exposed granddaughters in 
comparison eGFP controls (Fig 3D). Interestingly, the overall number of copy 
number alterations appears to correlate positively with the overall number of 
cytosine mutations, suggesting that many A3B-catalyzed genomic DNA 
deamination events are likely processed into DNA breaks and result in larger-
scale copy number aberrations (Fig 3E). 
 
A3B mutational landscape by whole genome sequencing  
Next, whole genome sequencing (WGS) was done to assess the mutation 
landscape for 3 A3B-eGFP exposed and 3 eGFP control granddaughter clones 
from two distinct biological replica experiments (granddaughters in Fig. 3A). 
Samples were sequenced using the Illumina X Ten platform at the Beijing 
Genome Institute. Approximately 700 million 150 bp paired-end reads were 
generated for each genome, with an average read depth of 34.5 ± 2.8 (SD) per 
locus. Reads were aligned against the hg19 genome with BWA and somatic 
mutations were called using both VarScan2 (Washington University, MO) and 
MuTect (Broad Institute, MA), with the intersection of the results these two 
methods identifying unambiguous mutations for further analysis (98,99). 
Using this conservative approach for mutation identification, a total of 
6741, 3496, and 3530 somatic mutations occurred at cytosines in granddaughter 
clones that had been subjected to 10 rounds of A3B-eGFP pulses in comparison 
to only 910 and 1531 cytosine mutations in the eGFP controls, consistent with 
the results of the SNP analyses described above (p=0.018, Student’s t-test; Fig 
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4A). In particular, the A3B-eGFP pulsed granddaughter clones had higher 
proportions of C-to-T mutations than the eGFP controls, 59%, 52%, and 54% 
versus 36% and 47%, respectively (red slices in pie graphs in Fig 4B). The A3B-
eGFP pulsed granddaughter clones also had higher proportions of mutations at 
A/T base pairs suggesting that genomic uracil lesions introduced by A3B may be 
processed by downstream error-prone repair processes analogous to those 
involved in AID-dependent somatic hypermutation of immunoglobulin genes (6) 
(Fig 4A).   
However, despite finding significantly higher base substitution mutation 
loads in A3B-eGFP pulsed granddaughter clones, the overall distributions of 
cytosine mutations within the 16 possible trinucleotide contexts appeared visually 
similar for the A3B-eGFP and eGFP controls (histograms comparing the absolute 
frequencies of cytosine mutations with the 16 possible trinucleotide contexts are 
shown in Fig 4C). This result was initially surprising because we had expected 
obvious differences between the A3B-induced mutation spectrum and that 
attributable to other mechanisms, particularly within 5’TC contexts. However, a 
closer inspection of the eGFP control data sets strongly indicated that this 293-
based system is defective in post-replication mismatch repair. For instance, the 
eGFP controls had large numbers base substitution mutations (predominantly C-
to-A, C-to-T, and T-to-C) as well as hallmark microsatellite instabilities consistent 
with reported mutation spectra in mismatch repair defective tumors (65,100). 
Moreover, each eGFP control had over 10,000 insertion/deletion mutations 
ranging in size from 1 to 46 base pairs (constrained by the length of the Illumina 
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sequencing reads).  
Therefore, to distinguish the A3B-eGFP mutational contribution from that 
caused by mismatch repair deficiency, we used NMF decomposition via the 
Somatic Signatures R package to extract mutational signatures from all 
granddaughter clones (Methods). Extracted signature 1 (E1) contained minimal 
C-to-A mutations and the overall proportion of C-to-T mutations was increased 
greatly compared to the raw profiles observed for each sample. This contribution 
of this signature to the overall mutation profile was specifically enriched in the 
A3B-eGFP pulsed granddaughter clones, contributing to about 50% of all 
mutations (Fig 4E). Notably, this signature shows significant enrichments for C-
to-T mutations within 5’TCG motifs, which are biochemically preferred by 
recombinant A3B enzyme (5,22,23) (Fishers exact test for granddaughter clones 
CA1/CA3: TCA, p=0.42/0.93; TCC, p=1.00/0.96; TCG, p < 0.0001/0.0001; and 
TCT, p=1.00/0.46). Moreover, strong enrichments for C-to-G transversion 
mutations were evident for cytosine mutations within TCW contexts (W=A or T) in 
E1 in comparison to other trinucleotide combinations (p=0.027, Student’s t-test). 
C-to-G transversions are hallmark A3B-mediated mutations as other cytosine-
biased mutational processes such as ageing (spontaneous deamination of 
methyl-cytosines in 5’CG motifs) and UV-light (polymerase-mediated bypass of 
cross-linked pyrimidine bases) primarily result in C-to-T transitions (26,63). 
Extracted signatures 2 (E2) and 3 (E3) were characterized by larger proportions 
of C-to-A mutations occurring independently of trinucleotide motif. Upon 
clustering our extracted signatures with previously defined mutation signatures 
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(65), E2 and E3 appeared most similar to signature 16, which currently has no 
known etiology. Unexpectedly our APOBEC-mediated signature, E1, clustered 
most closely to signature 5, also of unknown etiology, rather than signatures 2 or 
13, which are normally attributed to APOBEC-mediated mutagenesis. These 
WGS data suggest that the “APOBEC” signature may be more complex than 
anticipated from prior studies. Nevertheless, our WGS studies demonstrate 
increased genome-wide mutagenesis attributable to A3B, even over additional 
pre-existing mutational process in this human 293 cell-based system.  
 
Discussion 
A3B is emerging as a significant source of somatic mutation in many different 
cancer types (reviewed by (27,62–64) and see Introduction for references to 
primary literature). Here, we further develop a 293-based cellular system for 
conditional, Dox-mediated expression of A3B. The system was validated using 
flow cytometry, immunoblotting, enzyme activity assays, and, most importantly, 
three complementary mutation detection methods (3D-PCR, SNP microarray, 
and WGS). Our results demonstrate higher levels of cytosine-focused mutations 
in A3B-eGFP expressing cells, in comparison to eGFP controls. In particular, C-
to-T transition mutations and C-to-G transversion mutations in A3B preferred 
trinucleotide motifs predominated after the composite mutation spectra were 
extracted into 3 separate signatures. These studies combine to fortify the 
conclusion that A3B is a potent human genomic DNA mutagen.  
An unexpected outcome of our studies was the discovery of a probable 
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defect in post-replication mismatch repair in the 293-based system. The 
mismatch repair-defective phenotype is clear with hallmark microsatellite 
instabilities and base substitution mutation biases. However, the molecular 
nature of this defect is not obvious and may be genetic and/or epigenetic. For 
instance, the WGS data show 6 exonic and over 100 intronic alterations to 
mismatch repair and related genes that could induce a mismatch repair defective 
phenotype. Our results are consistent with a prior WGS study that found 1000’s 
of mutational differences between 6 different 293-derived cell lines, as well as 
significant down-regulation of MLH1 and MLH3 in a subset of the lines (101). Our 
studies are also consistent with at least two additional prior reports characterizing 
the related 293T cell line as mismatch repair defective (102,103). Regardless of 
the precise molecular explanation(s), given the large number of labs worldwide 
that rely upon 293 or 293-derived cell lines, the results presented here are likely 
to be helpful for informing future experimental designs using this system. 
Despite a compelling case for A3B in cancer mutagenesis (key results 
cited in the Introduction), the overall APOBEC mutation signature in cancer 
cannot be explained by A3B alone, because it is still evident in breast cancers 
lacking the entirety of the A3B gene due to a common deletion polymorphism 
(104). One or more of the other APOBEC family members with an intrinsic 
preference for 5’TC dinucleotide substrates may be responsible. For instance, a 
leading candidate is A3A due to high catalytic activity in biochemical assays, 
nuclear/cell-wide localization in some cell types, propensity to induce a DNA 
damage response and cell death upon overexpression, and the resemblance of 
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its mutation signature in model systems to the observed APOBEC signature in 
many cancers (11,12,14,22,28,87,94,105–110). A3A gene expression may also 
be derepressed as a side-affect of the A3B gene deletion(111). Additional studies 
will be needed to unambiguously delineate the identities of the full repertoire of 
cancer-relevant APOBEC3 enzymes, quantify their relative contributions to 
mutation in each cancer type, and build upon this fundamental knowledge to 
improve cancer diagnostics and therapeutics. 
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Fig	1.	A	conditional	system	for	A3B	expression.		
(A) Representative flow cytometry data for T-REx-293 A3B-eGFP and eGFP 
daughter cultures 24 hrs after Dox treatment (n=3; mean +/- SD of technical 
replicates).  
(B) Representative anti-GFP immunoblot of T-REx-293 A3B-eGFP and eGFP 
daughter cultures 24 hrs after Dox treatment.  
(C) Representative DNA cytosine deaminase activity data of whole cell extracts 
from T-REx-293 A3B-eGFP and eGFP daughter cultures 24 hrs after Dox 
treatment. 
(D, E, F) Biological replicate data using A-series daughter clones of the 
experiments described in panels A, B, and C, which used C-series daughter 
clones. 
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Fig	2.	A3B	induction	optimization	and	targeted	sequencing	results.  
Fig	2.	A3B	induction	optimization	and	targeted	sequencing	results 
(A, B) Dose response curves indicating the relative colony forming efficiency 
(viability index) of T-REx-293 A3B-eGFP daughter clones treated with the 
indicated Dox concentrations (n=3; mean viability +/- SD of biological replicates). 
The dotted lines show the Dox concentration required to induce 80% cell death 
(2 or 1 ng/mL for C- and A-series daughter clones, respectively). 
(C) A schematic of the experimental workflow depicting the viability index of a 
population of cells induced to express A3B-eGFP and recover over time. Dox 
treatment occurs on day 1, maximal death is observed on days 3 or 4, and each 
population typically rebounds to normal viability levels by days 6 or 7.  
(D-G) A summary of the base substitution mutations observed in MYC (241 bp) 
and TP53 (176 bp) by 3D-PCR analysis of genomic DNA after 10 rounds of A3B-
eGFP or eGFP exposure. Red, blue, and black columns represent the absolute 
numbers of C-to-T, C-to-A, and other base substitution types in sequenced 3D-
PCR products, respectively. Asterisks indicate cytosine mutations occurring in 5’-
TC dinucleotide motifs. The adjacent pie graphs summarize the base substitution 
mutation load for each 3D-PCR amplicon. The number of sequences analyzed is 
indicated in the center of each pie graph.  
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Fig	3.	SNP	analyses	to	estimate	new	mutation	accumulation.	
(A) A dynastic tree illustrating the relationship between mother, daughter, and 
granddaughter clones used for SNP and WGS experiments. The red, dashed box 
around the daughter clones denotes 10 cycles of Dox-treatment. 
(B) A histogram summarizing the SNP alterations observed in granddaughter 
clones by microarray hybridization. Red, blue, and black colors represent C-to-T, 
C-to-A, and C-to-G mutations, respectively.  
(C) Sanger sequencing chromatograms confirming representative cytosine 
mutations predicted by SNP analysis. The left chromatogram shows a G-to-A 
transition (C-to-T on the opposite strand) and the right chromatogram a C-to-G 
transversion. 
(D) A histogram plot of the total number of copy number (CN) alterations in the 
indicated categories in A3B-eGFP exposed granddaughter clones in comparison 
to eGFP exposed controls.  
(E) A dot plot and best-fit line of data in panel B versus data in panel D. 
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Figure	4.	Summary	of	somatic	mutations	detected	by	WGS.	
(A) Stacked bar graphs representing total number of C/G and T/A context 
somatic mutations in each granddaughter subclone (black and white bars, 
respectively). A1 and A3 are A3B-eGFP exposed subclones, and G1 and G2 are 
eGFP exposed controls. 
(B) Pie charts representing the proportion of each type of cytosine mutation 
across the genome. Red, blue, and black wedges represent C-to-T, C-to-A, and 
C-to-G mutations, respectively. A1 and A3 are A3B-eGFP exposed subclones, 
and G1 and G2 are eGFP exposed controls. 
(C) Stacked bar graphs representing the absolute frequency of C-context somatic 
trinucleotide mutations of each subclone from the B panel. 
(D) Stacked bar graphs representing the extracted mutation signatures from 
WGS data.  
(E) The proportion that each extracted mutation signature contributes to each 
granddaughter clone. 
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Overview 
Personalized medicine includes the identification of the biomarkers and/or 
expression profiles important in the treatment of cancer. Cancer cell lines offer a 
representative diversity of molecular processes involved in both malignant 
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phenotypes as well as therapeutic responses. Coupling cancer line expression 
with high-throughput drug screens allows for examination of perturbed pathways 
that influence drug sensitivities. Here we use The Sanger Institute’s Genomics of 
Drug Sensitivity in Cancer to develop a bioinformatic and pathway analysis 
approach that identifies the BCR pathway as an important biomarker in response 
to the tyrosine kinase inhibitor, dasatinib, used in hematologic cancer therapies. 
This approach establishes a process by which data from cell line repositories can 
be used to identify biomarkers associated with drug response in the treatment of 
cancers. 
Introduction 
Despite improvements in cancer therapies, wide variation in tumor 
response to treatment is a major limitation in achieving consistent therapeutic 
effect(1,2). The variation is likely represented by tumor diversity. Previously, we 
demonstrated computational approaches to define response and resistance 
based on gene expression profiles in myeloma, a plasma cell malignancy (3). 
This approach took advantage of a large panel of myeloma cell lines 
representing a wide diversity of response to therapeutic drugs used in the 
clinic(4). 
 Numerous collections of cancer cell lines provide additional opportunities 
to characterize the genetic signatures that may distinguish response and 
resistance to a variety of drugs. The NCI-60, Cancer Cell Line Encylopedia 
(CCLE), and the Genomics of Drug Sensitivity in Cancer (GDSC) provide a 
wealth of information that includes genomic sequences, mutational status, gene 
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expression, as well as response to panels of drugs used in cancer therapies (5–
7). This offers a unique opportunity to apply approaches that may provide genetic 
profiles that define response and resistance, with the potential to apply these as 
predictors in clinical decisions. 
 The GDSC is a collection of 1,047 cell lines from diverse tumor types that 
have been tested with 265 drugs (5). The data collection includes DNA 
sequence, mutation status, and gene expression data that we have used to 
develop a pipeline of computational approaches that predict response and 
resistance. Drug response is determined by a 9 step 2-fold serial dilution of drug 
concentration and measuring cell viability. From these, two quantitative values 
are provided: the drug concentration required to reduce viability by 50% (IC50) 
and the area under the dose-response survival curve (AUSC). Gene expression 
data is available from the Affymetrix U219 gene array platform.  
 Because expression patterns may vary widely simply based on tissue 
specificity, we chose to limit our initial analysis to B cell malignancies, 
represented by 71 cell lines derived from leukemias, lymphomas, and myelomas. 
Our approach comprises a series of steps in which we classify response and 
resistance, develop a differential classification profile of gene expression 
patterns, identify features by pathway analysis, and validate on cell lines and 
reported clinical outcomes (Fig 1). We demonstrate this approach to stratify and 
predict response to the protein tyrosine kinase inhibitor, dasatinib.  
 Dasatinib is a multi-target kinase inhibitor that has affinity for about 50 
kinases and is most widely used to manage chronic myelogenous leukemia (8–
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12). Dasatinib’s ability to reversibly and competitively inhibit the ATP binding site 
of kinases make its potential applications wide in scope. However, therapeutic 
applications have been reported in multiple cancers with significant variation in 
response(13–16). For this report, we develop an approach that identifies a 5 
gene signature distinguishing dasatinib response and resistance. 
Methods 
Expression Analysis 
Robust-Multi-Array Average (RMA) normalized expression data and drug 
response data was downloaded directly from the GDSC website 
(www.cancerrx.org). 
CCLE Robust-Multi-Array Average (RMA) normalized expression data 
was downloaded from Genomicscape.com. Multiple ENSEMBL IDs mapping to 
the same gene region were averaged.  
Normalization of CCLE values GDSC  
There are 48 cell lines of B-cell origin that are in both the GDSC and the 
CCLE.  These were used to determine the best method of normalization. Lowess 
plot comparison between these 48 lines showed the best concordance between 
the two sets. First, the natural log of each CCLE intensitiy value was subtracted 
from that value, then the set was quantile normalized to the GDSC. The 
Bioconductor limma package normalizeQuantile function was modified to adjust 
the CCLE values to their GDSC “twin” lines(17). 
R scripts available by request. 
Statistical Analysis 
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The Significant Analysis of Microarray (sam) function of the siggenes R 
package was used in differential expression analysis (18,19).  The thresholds 
were varied until the number of genes exceeded 200, yet still within an FDR of 
0.10. 
Responders and Non-Responders expression values for each gene in the 
signature were compared using the unpaired, nonparametric, Mann-Whitney test 
in GraphPad (Prism). 
Ordinary one-way ANOVA was performed in GraphPad (Prism) on all 
genes of signature using 4 groupings based on response values: Responders 
(AUSC<0.75), Partial Responders (AUSC 075-0.85) and Limited Responders 
(AUSC 0.85-0.98), and Non-Responders (AUSC>0.98). 
The cor() function of the R stats package was used to find Pearson 
correlation coefficients using all expression values between cell lines (20). 
All heatmaps, including the Pearson correlation coefficients were rendered 
using the pheatmap package (21). 
Tissue Culture 
All cell lines were maintained in RPMI-1640 (Lonza) supplemented with 
10% FBS (Invitrogen Life Technology), 1X Antibiotic/Antimycotic (Gibco), 1X L-
Glutamine (Gibco), and 1ng/mL of human IL-6. Incubators were humidified and 
maintained at 37° Centigrade with a 5% CO2 content. 
Cells were plated at a concentration of 5x105/mL on day0. On day 1, a 
dilution series of concentrations (2-fold dilutions from the max dose of 5.12µM) 
as well as a DMSO vehicle control were administered in triplicate. On day 4 (72 
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hours after treatment) cell viability was measured by Cell Titer-Glo Luminescent 
cell viability assay according to manufacturer's instructions (Promega) and 
luminescence was read  and recorded using Synergy 2 Microplate Reader 
(Biotek).  
Maximum viability assigned, as 100% for IC50 or 1 for AUSC calculations, 
was normalized to untreated controls. IC50values were estimated by calculating 
the nonlinear regression using the inhibitor-normalized response equation 
(variable slope) in GraphPad (Prism).  
As done in the calculation of AUSC in the GDSC, wells containing media, 
drug, but no cells were used to calculate the value for normalizing maximum 
response, which corresponds to a 0 value. AUSC used the concentrations that 
overlapped with GDSC doses and substituted the first lowest concentration within 
the GDSC dilution series for the lower 2 doses tested in lab. AUSC were 
calculated using GraphPad (Prism). 
Results 
Classification of Response and Resistance. 
The first step in the process is shown in Figure 2, in which we arranged 
the 71 B cell lines by response, using both Area Under the Survival Curve 
(AUSC) and IC50. The distribution of response favored non-response, with only 
14 lines showing a strong response to low doses, and 11 lines showing 
essentially no response. Specifically, we classified Responders as lines that 
show an AUSC <0.75, and an IC50 value < maximum drug concentration divided 
by 4 and Non-Responders were defined as having an AUSC>0.98 and an IC50 > 
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maximum dose tested. This resulted in the 14 strong Responder lines versus 11 
highly resistant (Non-Responder) lines, representing the extreme ends of 
response and resistance. Our rationale was that underlying this wide separation 
of response may be a common expression signature or pathway(s) that can 
serve as a predictive biomarker.  
We applied Pearson correlation coefficient analysis on all 71 cell lines 
(see methods). Notably, Responders shared more similarity than Non- 
Responders (rank-sum p = 4.97x10-10) (Fig 2B,C). What is apparent is the Non-
Responders, as a group, are far more diverse in gene expression than those 
cells that are within the Responder group. Thus, we directed our attention to the 
features that define the Responders that are distinct from the gene expression of 
the diverse Non-Responders.  
Differential Gene Expression and Feature Selection 
Differential gene expression between the Responder and Non-Responder 
lines was performed using Significance Analysis of Microarray (see methods), 
with a False Discovery Rate limited to 10%. This resulted in 228 genes to further 
analyze for their relevance to the dasatinib response. 
Ingenuity Pathway Analysis (IPA) (Qiagen) uses an extensive, curated 
literature bank to identify molecule interaction and pathway regulation (23). Data 
is uploaded and populates the knowledge base interactions. Significant p-values 
are generated when genes fall within a pathway in a non-random manner. 
Further, pathway activation scoring is achieved by similarly populating relevant 
pathways and the directionality of the gene expression. Analysis of major 
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canonical pathways provides both the p-value (likelihood of true positive) and z-
score (directional impact of activation/de-activation). 
Pathway analysis was conducted using IPA on the 228 differentially 
expressed genes and their log-fold ratio data of Responders relative to Non-
Responders. Notably, the top canonical pathway with a significant z-score (z-
score=2, which is 2 standard deviations from the mean) was the B-cell-receptor 
(BCR) pathway (p-value=0.013). Using the log-fold ratio scores of Responders 
relative to Non-Responders, molecules of the BCR pathway reflected a uniquely 
activated pattern in the Responders(Fig 3).  
BCR and B-cell Development 
 The BCR pathway has been demonstrated to be active at different stages 
of B cell development (24–26). Activation of various oncogenes and tumor 
suppressor genes gives rise to the malignancies at different stages of B-cell 
development (Fig. 4). The distribution of response to dasatinib along the B-cell 
differentiation path indicates cancers arising from a pre- or early- B-cell may be 
more likely to respond than B cells or plasma cells later in development that 
notably have decrease expression of BCR pathway genes.  
Evaluation of the Genes in the BCR Pathway 
We further characterized the differentially expressed genes of the BCR 
pathway between the Responders (high expression) and Non-Responders (low 
expression). The genes from the BCR pathway were analyzed using t-test 
between Responders and Non-Responders.  Genes that were significant (p-
value <0.05)  were further analyzed.   
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Mann-Whitney tests of individual genes of the BCR pathway were 
performed. We reasoned that effective drug-response predictors would also 
show a linear trend between Responders, intermediate groups, and Non-
Responders.    
Intermediate response groups were included to identify an expression 
trend across the full range of responses. These groupings included cell lines with 
a partial response (AUSC between 0.75-0.85) and limited response (AUSC 
between 0.85-0.98). The 5 genes displaying the best separations were chosen 
for use in a predictive scoring system described below.  Significant p-values 
between adjacent groupings were not observed. However, ANOVAs were 
performed using all 4 groupings and indicated 4 of the 5 genes showed highly 
significant differences between the Responders and Non-Responders (ANOVA 
p-values listed underneath Mann-Whitney test p-values in Fig 5), and trends of 
decreasing expression across the increasing resistance groupings. The 
expression of the 5 genes is shown as a heatmap comparing the strong 
Responders and the highly resistant Non-Responders (Fig 6). Notably, CD19 
alone showed a significant association with response (p<0.0001). 
Validation 
Independent Cell Lines 
Eleven cell lines not included in the differential expression analysis had 
available gene expression data (8 from CCLE, 3 from GDSC). These were tested 
in-house for dasatinib response. The CCLE/GDSC expression platforms were 
then normalized to one another to obtain comparable values (not shown). During 
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the validation phase, we used the AUSC as the sole metric indicating response. 
The binary classification of these lines based on the 5 gene signature into 
Responder (AUSC<0.8) and Non-Responder (AUSC>0.8) demonstrated the 
previously modeled BCR expression associated with response in 9 of the 11 
lines (Fig 7). 
An algorithm was developed from the averaging the expression values of 
the Responders and Non-Responders, we refer to these as Response Averages 
(RA).  Lines that had expression lower than the RA of CD19 were immediately 
binned as a Non-Responder.  Lines that had expression higher than that of the 
CD19 RA were given a score of “1” for each gene the expression exceeded the 
RA of EBF1, PAX5, BTK, and BLNK.  If a cell line’s score was less than 3, they 
were binned as Non-Responders. 
The discriminating genes were determined using the extreme Responders 
versus the extreme Non-Responders. When applying the scoring system to the 
intermediate responding lines (that were not included in the gene discrimination 
modeling) 30 lines were correctly predicted for an accuracy rate of 67%. It should 
be noted low CD19 does place 23 out of 23 of these cell lines in the Non-
Responder category.  Thus, low CD19 is an effective discriminator of non-
response.  Nevertheless, the 5 gene discrimination was very accurate in 
distinguishing the highly sensitive from the highly resistant lines. Despite the 
difficulty of determining the response of the equivocal intermediate group, the 
sensitivity of the test set, training set, and intermediate group is 78.9% and 
specificity is 74.6%. 
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Clinical Associations 
MM lines (plasma cells) rarely express CD19, and show a low activation of 
the BCR pathway.  Thus, our BCR gene discrimination model would indicate 
poor response.  Indeed, a recent clinical study (NCT00429949) of relapsed, 
refractory, or plateau phase MM patients was discontinued after using dasatinib 
as a single agent in which a partial response occurred in only 1 of 21 enrolled in 
the study.  
 Waldenström’s macroglobulinemia (WM) is also a plasma cell 
malignancy, but in contrast to multiple myeloma, is CD19+, and has recently 
been described to express an activated BCR pathway (27). Based on our 5 gene 
signature we predicted these malignancies would respond to dasatinib; thus, 
representing an independent validation set of Responders. Indeed, WM primary 
patient lines exhibited good response to dasatinib in primary patient samples 
(n=32)(27) supporting our findings that the expression of CD19 and 4 other 
molecules of the BCR pathway are associated with dasatinib response.  A 
comparison of the 5 gene expression of the WM patients and MM cell lines 
shows the stark difference in expression between these two plasma cell 
malignancies (Sup Fig 1). 
Bortezomib Resistance, CD19, and Collateral Dasatinib Sensitivity 
Further supporting the findings here is work done in mantle cell lymphoma 
(MCL). MCL is mid-stage B-cell malignancy and may, or may not, express CD19 
(28,29). Two MCL lines were treated with low doses of Bortezomib over time to 
better understand mechanisms of resistance in MCL (30). This acquired 
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bortezomib resistance (BTZ-R) was accompanied by a re-activation of the BCR 
pathway, ie. these cells had increased expression and phosphorylation of BCR 
components above parental lines. Notably, along with this re-activation, a 
collateral increase in sensitivity to dasatinib was observed. The BTZ-R lines 
responded to doses of dasatinib 10-fold less concentrated than parental lines. 
These observations held true in mouse xenografts of the MCL line pairs treated 
with dasatinib as well (30). These data further support that CD19 and the BCR 
pathway are consistent biomarkers associated with B cell lineage cells response 
to dasatinib. 
 To further explore the possibility of acquired bortezomib resistance 
inducing a collateral sensitivity to dasatinib, we tested the sensitivity of a 
myeloma cell line pair. U266-P and U266-VR (Velcade resistant) was developed 
in our laboratory and had RNAseq data available (130). The U266-VR line had a 
2.8-fold increase in FPKM reads for CD19. In addition the U266-P line had a 
dasatinib AUSC value of 0.91, whereas U266-VR had an AUSC of 0.73. This 
supports the observations of Kim, et al. and also lays the groundwork for 
exploring the bortezomib-dasatinib relationship further in multiple myeloma. 
Discussion 
We describe the dasatinib response of B-cell malignancies as two 
extremes: Responders and Non-Responders. From this binary categorization, 
comparisons were made between the groups. Differential expression revealed a 
set of genes, that, when uploaded to IPA, was most significant for the BCR 
pathway. The Responders had an activated pathway and conversely, the Non-
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Responders had a de-activated BCR pathway. Five genes: CD19, EBF1, BTK, 
BLNK, and PAX5, of this pathway were used to sort the 25 original cell lines into 
their Responder/Non-Responder groupings. 
Eleven independent cell lines were likewise binned according to their 
expression values for each of the five genes. Ten of the 11 were appropriately 
categorized. WM patient primary samples have expression patterns indicative of 
response. As a malignancy, WM primary cell lines are responsive to dasatinib 
(27). The expression of the 5 BCR genes, and particularly CD19, showed 
effective discrimination of the strong responders and highly resistant cell lines.  
 We show here that cell line expression and drug response can be 
interrogated through differential expression and pathway analysis to find 
meaningful relationships and identify biomarkers of drug response. However, 
there are potential limitations. First, the modeling was done with a very limited 
number of cells, at the extremes of response. Despite this, the associations 
identified in the limited modeling set provided a robust association with actual 
clinical outcomes. The predictive power in a clinical setting may not be accurate 
in identifying partial responses, nor the increased efficacies that often 
accompany combination therapies. However, we note myelomas with emerging 
proteasome inhibitor resistant populations that may contribute to relapses, may 
respond to dasatinib, and possibly benefit from its use in combination therapies.   
The modeling also takes into account only the diversity of tumor cells, without 
consideration of variations in microenvironmental influences or patient variations 
	 70	
in drug metabolism or distribution. Yet, the patient correlations remained 
significant to predict response across the B cell developmental pathway.  
This is just one example of the use of available data bases to develop 
response signatures. Similar approaches may provide gene signatures across 
many other drugs within the GDSC, CCLE, or similar large cell line data bases.  
Ultimately, expression signatures may add important biomarkers that better direct 
therapeutic approaches, 
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Fig 1. Workflow 
A) Cell lines representing B cell malignancies and showing strong response 
and strong resistance to disatinib were chosen.  
B) Differential expression using sig.genes with an FDR of <0.10 was used to 
describe potential genetic biomarkers of response.	 
C) Gene lists and fold change expression were analyzed using Ingenuity 
Pathway Analysis.	 
D) Mann-Whitney tests were performed on extreme Responders/Non-
Responders followed by ANOVA analysis to determine expression trends 
across response.	 
E) Statistically significant genes defined a gene signature and were used to 
separate cell lines by response. 
F) Untested lines and clinical samples were used to validate the gene 
signature. 
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Fig. 2 Diversity of Dasatinib Response and Expression 
Correlation 
A) The 71 B-cell malignancies found in the GDSC with dasatinib data are plotted 
along the x-axis in increasing order of AUSC value. Both log2(IC50) values 
(black boxes, scaled on the primary axis) and AUSC scores (gray circles, scaled 
on secondary axis) are represented. 
B-C) Pearson correlation coefficients calculated using all available 17,419 gene 
expression observations within the GDSC. Perfect correlation coefficients of 1 
can be seen along the diagonal as each cell line is compared to itself. The lowest 
correlation coefficients are found between Non-Responders indicative of their 
expression diversity.  
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Fig 3. BCR Pathway Activated in Extreme Responders 
Genes of the BCR pathway represented as expression ratios of highly sensitive 
Responders relative to Non-Responders. The darker the red-colored molecule 
represents a greater fold-change between groups. 
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Fig 4. B-cell Differentiation Stages with Malignancy and CD19 
Expression of Cell Lines 
Maturation of B-cells is represented from left to right. Malignancies arising from 
corresponding stages of B-cell development are depicted along with cell lines 
representing those malignancies in the same vertical axis. Next to cell line names 
are either a red dot (Responders) or blue dot (Non-Responders) along with their 
corresponding log2 fluorescence intensity of CD19, the marker found most 
associated with dasatinib response. 
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Fig 5. Statistically Significant Signature Genes 
Each Gene in the 5 gene signature is represented with cell lines binned 
according to AUSC and their log2 expression values. The discrimination of 
categorical response is depicted in the graph below as the following 4 categories 
with AUSC values following parenthetically: Responder (0-0.75), partial 
Responder (0.75-0.85), limited Responder (0.85-0.98), and Non-Responder 
(>0.98). Mann-Whitney tests p values assessing the Responders versus Non-
Responders are listed above the p values for ANOVA across all categories. 
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Fig 5. Statistically Significant Signature Genes
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Fig 6. Gene expression Signature of Extreme Response 
 
Unsupervised clustering of the gene expression signature that discriminates 
Responders from Non-Responders Cell lines are listed along the x-axis while the 
5 genes most associated with dasatinib response are on the y-axis. Expression 
values are represented as scaled as z-scores of the log2 transformed 
fluorescence intensities. The 14 extreme Responders are boxed in red on the left 
of the heatmap, the 11 extreme Non-Responders are boxed in blue on the right. 
The dynamic ranges of each gene in the signature is not always reflective of its 
contribution to identifying response as can be seen in the case of PAX5. This 
gene is highly significant in differentiating response, but its absolute values vary 
subtly, but significantly (see Figure 5, p<.0001). 
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Fig 7. Validation of Lines With 5 Gene Signature 
 
Training and Test Lines are evaluated based on their expression values relative 
to the extreme responding lines. Lines with expression values less that the 
average of the Responders and Non-Responders of the training set are binned 
into Responder and Non-Responder. Test set of 11 cell lines had 1 true positive, 
2 false positives, 8 true negatives, and no false negatives.  
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Supplementary Fig 1. Expression Comparison between multiple 
myeloma and Waldenström’s macroglobulinemia 
Sixteen MM cell line and 57 WM primary patient samples had RNAseq available 
for comparison of the 5 genes associated with dasatinib response. Each 
sample’s gene expression value is represented as a fraction of the total number 
of reads for that sample
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Chapter	4	
Discussion and Future Aims 
My thesis work can be described by two words: differences and 
similarities. In Chapter 2, I described an endogenous mutagenic process that 
contributes heterogeneity--differences. In Chapter 3, I describe a 5 gene 
expression signature predictive of dasatinib sensitivity. Non-Responders have 
low expression of these genes, Responders have higher expression—similarities.  
Mutational Processes 
In Chapter 2, I introduced a mechanism of endogenous mutagenesis that 
contributes to cancer heterogeneity. Our work proved that A3B overexpression 
mutates genomic DNA in human cell lines. The extent of the phenotypic changes 
that result from this process is an area of active research. This work showed A3B 
mutagenesis in human genomic DNA occurs most often at the sequence context 
previously described in in vitro work (22).  
 Future Directions 
Comparison of the whole genome sequences of the control clones 
provided evidence of a background mutagenic process in the T-REx-293 lines 
used. The 293 line and its derivatives (such as the T-REx-293 used in this study) 
are widely used. Researchers should be aware of this feature of the 293 line as it 
may be an inappropriate choice for some studies. For example, 293 lines are not 
ideal in studies that assume no microsatellite instability. 
Future study to better understand the source and extent of the apparent 
mismatch repair deficiency is also be important for repair research. Down-
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regulation of the mis-match repair genes, MLH1 and MLH3 have been found in 
293-derived lines previously (101). The WGS revealed mutations of mismatch 
repair genes in all clones indicating the original line procured commercially also 
contained the mutations. Are these mutated genes still functional? Does the 
down-regulation of either or both MLH1 and MLH3 cause the phenotype? 
Transfection experiments of MLH1, MH3, and the mutated versions of mismatch 
repair genes in our studies could rescue the defect and answer the above 
questions.  
Predictive Expression Profiles 
 In Chapter 3, we used pathway analysis to describe the expression of 5 
genes of the BCR pathway as important for response to dasatinib. Pathway 
analysis identified the BCR as the top canonical dysregulated. Study of 
heatmaps of the BCR components indicates that not all responders have 
upregulation of all BCR components, nor to the same degree (Fig 1). But taken 
together, the dysregulation was significant and consistent – providing novel 
understanding of factors that influence response.  
 Future Directions 
 Dasatinib is a multi-kinase inhibitor and can interact with multiple 
molecules of the BCR pathway (139). How does BCR pathway activation 
increase cell sensitivity to dasatinib? Is it a causal relationship or is BCR pathway 
activation a concomitant event? These questions can be addressed with 
transfection of dasatinib resistant lines and knock-down experiments of dasatinib 
sensitive lines. 
	 89	
 Importance of Pathway Analysis 
Differential expression does not always identify a dysregulated pathway. 
Each gene’s expression is evaluated independently of the networks or pathways 
in which it biologically connected. For example, a more restrictive FDR of 5% 
found 44 genes differentially expressed between dasatinib Responders and Non-
Responders, but only 2 of the 5 genes of the predictive response signature 
(PAX5 and CD19) were among those genes. After identifying the BCR pathway 
activation as important in dasatinib response, all genes of the pathway were re-
examined. This critical step identified the importance of BTK, which was not in 
the original 228 genes, in dasatinib response. This illustrates differential 
expression alone leaves out relationships between genes that are necessary to 
make clear what is biologically relevant. 
Personal Future Directions 
Large databases like the GDSC are resources, but underutilized. My work 
creates a workflow for identification of expression profiles of response (Ch 3, Fig 
1). In the future, I will preform similar analysis in the GDSC and CCLE to gene 
expression profiles for more drugs. I want to expand my analysis to include all 
265 drugs that show efficacy in B-cell malignancies. My goal is to create a 
hematologic-oncology expression chip that will direct physicians and patients to 
the most effective treatments for the patient’s specific malignancy (Fig 2).  
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Fig	1.	Genes	of	the	BCR	Pathway	
Responsive cell lines are represented on the left-most portion of the heatmap, 
boxed in red. Non-Responders are on the right, boxed in blue. The heatmap 
represents log2 (fluorescence intensity) values for 21 genes of the BCR pathway. 
This illustrates the patchwork nature of expression in response. This difficulty is 
overcome with pathway analysis when the genes that work together in a system 
are examined together as well. 
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Fig	2.	Potential	of	Expression	Profiling	in	Precision	Medicine	
 
The outline is a model for using expression signatures of response and non-
response for each drug (left panel). Patient Samples are assayed for their tumor 
profile (middle panel). Patient profiles are matched to responsive profiles of 
drugs. These matches result in the patient receiving therapy most likely to be 
effective. 
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